Heptacosanol

Sinopsis

Heptacosanol: A Comprehensive Encyclopedic Reference

1. Identity and Chemical Characterization

1.1 Chemical Names and Basic Identity

Heptacosanol — also known by the IUPAC-recommended name heptacosan-1-ol and commercially as 1-heptacosanol — is a long-chain, saturated, primary aliphatic alcohol. Its molecular formula is C₂₇H₅₆O, with a molecular weight of 396.73 daltons, a CAS Registry Number of 2004-39-9, and the IUPAC Standard InChIKey ULCZGKYHRYJXAU-UHFFFAOYSA-N. Additional synonyms recorded in reference databases include n-heptacosanol and NSC 53829.

Structurally, heptacosanol is a 27-carbon unbranched primary alcohol. Its general chemical formula is CH₃-(CH₂)ₙ-CH₂OH, with the chain length of the policosanol family varying from 24 to 34 carbon atoms. The "27" in heptacosanol denotes a 27-carbon backbone — the compound sits precisely between hexacosanol (C26) and octacosanol (C28) in the homologous series of very-long-chain fatty alcohols. Policosanol is the term for a mixture of long-chain primary aliphatic saturated alcohols; heptacosanol represents the 27-carbon member (1-heptacosanol) of this class, alongside 22-carbon docosanol, 24-carbon tetracosanol, 26-carbon hexacosanol, 28-carbon octacosanol, 29-carbon nonacosanol, 32-carbon dotriacontanol, and 34-carbon tetratriacontanol.

Like all members of the policosanol family, heptacosanol is a waxy, hydrophobic solid at room temperature. The policosanol class melts without decomposition and remains stable at temperatures up to 185 °C, and it has low solubility in water, with solubility reported at approximately 1.7 × 10⁻¹⁵ mg/ml at 25 °C and 2.5 × 10⁻¹⁵ mg/ml at 40 °C.

1.2 Membership in the Policosanol Class

Heptacosanol is one constituent of the group of compounds collectively known as policosanols. Policosanols are a common name for long-chain aliphatic primary alcohols consisting of 20–34 carbons, which include 1-tetracosanol, 1-hexacosanol, 1-heptacosanol, 1-octacosanol, 1-nonacosanol, 1-triacontanol, 1-dotriacontanol, and 1-tetratriacontanol. Within policosanol mixtures extracted commercially, heptacosanol is a minor constituent. The primary and most active component of policosanol is octacosanol (C28), which typically makes up between 60 and 66% of a high-quality policosanol extract; following octacosanol, the mixture contains descending concentrations of triacontanol (C30) and hexacosanol (C26), along with trace amounts of tetracosanol, heptacosanol, nonacosanol, and dotriacontanol.

2. Natural Sources and Botanical Occurrence

2.1 Principal Plant Sources

Heptacosanol occurs naturally as a minor component of plant cuticular waxes and epicuticular wax fractions found across a wide range of plant taxa. Policosanols, including heptacosanol, are found in a variety of plant organs — such as leaves, fruits, nuts, and seeds — and are isolated from various sources including beeswax, sugarcane, wheat, sorghum, brown rice, and maize.

Policosanol, and by extension its constituent heptacosanol, was originally isolated from sugarcane (Saccharum officinarum L.) wax. The major components of the commercial mixture are octacosanol (60–70% w/w), triacontanol (10–20% w/w), and hexacosanol (4–10% w/w); the mixture can also be extracted from beeswax, rice bran, and wheat germ. In sugarcane wax specifically, the long-chain aliphatic alcohols are isolated from purified sugarcane wax by hydrolytic cleavage.

Research into food sources has also detected heptacosanol in leafy vegetables. In addition to other confirmed policosanols, hexacosanol, heptacosanol, octacosanol, and triacontanol have been detected in Swiss chard (Beta vulgaris). Heptacosanol has further been reported as an isolate from woody plants; for example, heptacosanol and hentriacontane were isolated from Warburgia ugandensis.

2.2 Ecological Role in Plants

In its native botanical context, heptacosanol and related very-long-chain primary alcohols serve fundamental structural and protective roles. The aerial surface of higher plants is covered by a hydrophobic layer of cuticular waxes to protect plant tissues against environmental challenges including pathogen infection; as the first contact site between plants and pathogens, this layer of cuticular waxes functions as a physical barrier limiting pathogen entry, acts as a reservoir of signals to trigger plant defense responses, and provides cues exploited by pathogens to initiate infection. Biosynthetically, the cuticular wax mixture begins with elongation of C16 or C18 fatty acid–coenzyme A by the fatty acid elongase complex, and the elongated very-long-chain acyl-CoAs are then modified into aldehydes, alkanes, secondary alcohols, and ketones by the alkane-forming pathway, or into primary alcohols and wax esters by the alcohol-forming pathway. Heptacosanol, as a 27-carbon primary alcohol, is a product of this alcohol-forming pathway.

In research contexts, 1-heptacosanol is utilized to investigate the biosynthesis and function of cuticular waxes, providing insights into plant physiology and defense mechanisms.

3. Traditional and Historical Use

3.1 Context of Heptacosanol's Traditional Use

Heptacosanol was not historically isolated or used as a standalone compound in traditional medicine. Its traditional context is inseparable from that of the broader policosanol mixture, which was itself derived from food and agricultural sources widely consumed across cultures.

Sugarcane (Saccharum officinarum), the primary commercial source of policosanol and its constituent heptacosanol, has been cultivated and consumed in tropical and subtropical regions for millennia. However, the waxy fraction of sugarcane — from which policosanol concentrates are extracted — was not deliberately exploited for medicinal purposes in pre-modern traditions in the manner that specific plant parts or extracts were.

The deliberate use of policosanol as a dietary supplement began in the context of late 20th-century Cuban pharmaceutical research. Sugar Cane Policosanol (SCP) was used in Cuba as a dietary supplement since the early 1990s; today, Cuban SCP and policosanol isolated from other sources are widely used in supplements for hypercholesterolemia. Policosanol has been used as a lipid-lowering agent in Cuba since 1991.

The individual alcohols within policosanol were not isolated or used individually in any pre-modern pharmacopoeia. Heptacosanol's first appearance as a separately identified compound corresponds to 20th-century phytochemical analyses rather than to traditional ethnobotanical application.

3.2 Dietary Exposure Through Traditional Foods

While heptacosanol was never deliberately supplemented in traditional cultures, populations consuming sugarcane products, whole grain cereals, bran-rich rice, and beeswax-processed foods would have received trace dietary exposures to the policosanol mixture, including heptacosanol. Policosanol content in brown rice cultivars has been measured in the range of 2.4 mg/100 g to 10.7 mg/100 g, with the predominant components being octacosanol and triacontanol. Heptacosanol would represent only a fraction of this minor constituent pool.

4. Key Constituents, Chemistry, and Mechanisms of Action

4.1 Chemical Class and Structure

Heptacosanol belongs to the class of very-long-chain fatty alcohols (VLCFAs), distinguished from shorter-chain alcohols by having carbon backbones of 22 or more carbons. The major compositions of plant cuticular wax are very-long-chain fatty acids (C20–C40) and their derivatives, such as alkanes, aldehydes, ketones, esters, primary alcohols, and secondary alcohols. As a primary alcohol, heptacosanol carries a terminal hydroxyl group (-OH) at the C-1 position.

In biochemical studies, 1-heptacosanol is employed to explore its metabolism and enzymatic transformation within biological systems; researchers use it to study the activity of alcohol dehydrogenases and other enzymes involved in lipid metabolism, shedding light on the pathways and regulatory mechanisms of long-chain alcohol metabolism.

4.2 Metabolism: The Fatty Alcohol Cycle

The biological fate of very-long-chain alcohols such as heptacosanol is governed primarily by the fatty alcohol cycle, a peroxisomal metabolic pathway. Long-chain fatty alcohols are substrates for the fatty alcohol cycle, which converts these alcohols to their corresponding fatty acids. This oxidative conversion is of pharmacological importance because it generates the metabolites presumed to mediate pharmacological activity.

On the basis of demonstrations that fatty alcohol oxidation can be achieved through a reversible fatty alcohol cycle and that β-oxidation chain-shortening of very-long-chain fatty acids occurs in rat liver peroxisomes, researchers have speculated that policosanol-induced changes in hepatic cholesterol metabolism may be caused by the presence not only of aliphatic alcohols but also of very-long-chain fatty acids and chain-shortened secondary metabolites.

4.3 AMP-Kinase Activation and HMG-CoA Reductase Regulation

The leading mechanistic hypothesis for the cholesterol-relevant effects of policosanol — within which heptacosanol participates as a minor component — centers on activation of AMP-kinase (AMPK) and downstream regulation of HMG-CoA reductase, the rate-limiting enzyme of cholesterol biosynthesis.

Some studies demonstrate that policosanol promotes the phosphorylation of AMP-kinase in hepatoma cells, suggesting that this is the likely mechanism by which HMG-CoA reductase activity is reduced in treated cells. Policosanol decreased acetate incorporation into cholesterol without affecting the incorporation of mevalonate, indicating that these compounds act at or above HMG-CoA reductase; that is, policosanol interrupts or inhibits the metabolic pathway at a point preceding any action by HMG-CoA reductase itself, and policosanol did not directly inhibit HMG-CoA reductase.

Crucially, the relative contribution of heptacosanol specifically — versus other policosanol constituents — to this effect has been directly tested. Maximal inhibition by the full policosanol mixture yielded approximately a 30% decrease in [¹⁴C]acetate incorporation into cholesterol without cellular toxicity; however, octacosanol (C28), heptacosanol (C27), and hexacosanol (C26) individually yielded smaller and statistically insignificant decreases in cholesterol synthesis, whereas triacontanol (C30) replicated the inhibition obtained with the full policosanol mixture. This finding indicates that heptacosanol alone does not replicate the full cholesterol-synthesis-inhibiting effect of the policosanol mixture, and that triacontanol is the more pharmacologically relevant single constituent for this mechanism in vitro.

Intra-gastric administration of policosanol to mice increased the phosphorylation of hepatic HMG-CoA reductase and AMP-kinase by greater than 2-fold; siRNA-mediated suppression of fatty aldehyde dehydrogenase, fatty acyl-CoA synthetase 4, and acyl-CoA acetyltransferase in hepatoma cells prevented the phosphorylation of AMP-kinase and HMG-CoA reductase by policosanol, indicating that metabolism of these very-long-chain alcohols is required for the pharmacological effect.

4.4 Platelet Function

The potential benefit for conditions such as intermittent claudication is thought to be due to policosanol's ability to prevent platelets in the blood from sticking together and its potential anti-inflammatory activity. This antiplatelet aggregation effect is attributed to the policosanol mixture as a whole; there are no published studies isolating heptacosanol's specific contribution to this mechanism.

4.5 Antioxidant and Other Reported Properties

Policosanol — the mixture containing heptacosanol — exerts physiological effects including antioxidant, anti-inflammatory, and anticancer effects, and is reported to prevent aging-related and cardiovascular diseases, and to improve hypertension and hyperglycemia. These effects have been described primarily for the mixture, and individual attribution to heptacosanol is not established.

5. Scientific Evidence by Health Area

5.1 Important Methodological Note

No clinical trials exist that have investigated heptacosanol as an isolated, standalone supplement. All human clinical evidence pertains to policosanol — the mixture — which contains heptacosanol as a minor constituent. The following sections describe the state of evidence for policosanol, noting where heptacosanol's role has or has not been specifically examined. Evidence strength for heptacosanol per se is therefore extremely limited; it exists mainly as a component of a mixture under study, and has not been the subject of dedicated human pharmacology.

5.2 Lipid Metabolism and Cholesterol

Evidence strength: Inconsistent; the original Cuban studies have not been replicated by independent investigators.

Virtually all early clinical studies on policosanol were performed by a small group of investigators in limited centers, mainly in Cuba, and exclusively with policosanol from Cuban sugarcane; attempts to replicate these results outside of Cuba have failed to confirm the cholesterol-lowering effects of policosanol.

Over 1,000 subjects have been studied for periods of six weeks to one year in 15 randomized, placebo-controlled trials using policosanol (5 to 20 mg per day) for lipid lowering; at doses of 10 to 20 mg per day, significant reductions were observed for total cholesterol (17% to 21%) and LDL cholesterol (21% to 29%) with increases in HDL cholesterol (8% to 15%), though there are no data on efficacy determined by clinical endpoints. These results were generated predominantly by Cuban research groups.

A randomized, placebo-controlled, double-blind, parallel-group trial conducted by Berthold et al. used Cuban sugarcane-derived policosanol provided by Dalmer Laboratories in Cuba — the same supplement used in earlier studies — and observed no statistically significant difference between policosanol and placebo. The majority of trials testing policosanol outside of Cuba in the early 2000s used policosanol preparations from sources other than Cuban sugarcane wax, which may have been less potent; however, one rigorous trial conducted in Germany used the same formulation of policosanol (from Dalmer labs) as the Cuban trials, over a range of doses (10–80 mg), and also observed no consistent or significant impacts on lipid profiles relative to placebo.

While initial clinical trials primarily conducted by a Cuban research group indicated positive outcomes, subsequent independent studies have raised significant doubts about its effectiveness in lowering cholesterol.

The oral absorption and bioavailability of policosanol are limited and their exact lipid-lowering mechanisms have not been adequately elucidated.

5.3 Blood Pressure

Evidence strength: Preliminary; small, recent RCTs suggest modest effects, though research is primarily from Cuban groups.

One study reported the effects of 20 mg/day of policosanol on blood pressure in Cuban patients with prehypertension; the double-blind multicenter trial randomized 400 eligible patients into two strata of 200 patients each (prehypertension and Grade 1 hypertension). Policosanol exhibits lipid-modifying and beneficial vascular pleiotropic effects, and some previous Cuban trials found that policosanol lowered blood pressure in hypercholesterolemic patients; similar results were found recently in prehypertensive Asian subjects.

The exact way that policosanol could possibly lower blood pressure is not fully understood, and it may involve the renin-angiotensin-aldosterone system.

5.4 Platelet Aggregation and Intermittent Claudication

Evidence strength: Weak; human studies have not shown consistent benefit.

The potential benefit for intermittent claudication is attributed to policosanol's ability to prevent platelet aggregation and its potential anti-inflammatory activity; however, human studies have not shown it to consistently improve symptoms in people with intermittent claudication.

Policosanol has been studied in platelet aggregation and intermittent claudication, but data are insufficient to support this use.

5.5 Antioxidant Effects

Evidence strength: Preliminary clinical data; a single randomized controlled trial in statin users.

One study aimed to evaluate the effects of octacosanol supplementation on markers of redox status in cardiovascular patients on chronic atorvastatin therapy; a double-blind, randomized, placebo-controlled, single-centre study was conducted, assessing redox status homeostasis parameters including advanced oxidation protein products (AOPP), pro-oxidant-antioxidant balance (PAB), total oxidant status (TOS), total antioxidant status (TAS), superoxide dismutase activity (SOD), total protein sulfhydryl groups, and paraoxonase 1 (PON1) activity in 81 patients, who were classified into responders (n = 35) and non-responders (n = 46) and followed for 13 weeks. This study focused on octacosanol as the primary compound; heptacosanol was not specifically evaluated.

5.6 Anticancer Properties

Evidence strength: Preclinical only (cell lines and animal xenograft models); no human trials.

Policosanol extracted from Cuban sugarcane wax is reported to be a healthy functional food ingredient that helps improve blood cholesterol levels and blood pressure; its various physiological activities, such as antioxidant, anti-inflammatory, and anticancer activities, have been reported recently; the therapeutic efficacy in gastric xenograft models was investigated, finding that policosanol significantly inhibited gastric cancer cell viability and delayed tumor growth without toxicity in the SNU-16-derived xenograft model. This research involved the policosanol mixture, not isolated heptacosanol, and represents preclinical evidence only.

5.7 Metabolic and Adipose Effects

Evidence strength: Animal studies only; no human trials for this application.

Policosanol is a mixture of very-long-chain saturated fatty alcohols purified from natural sources such as rice bran, wheat, sugarcane, and beeswax; previous studies have demonstrated that octacosanol — the primary component — suppresses high-fat-diet-induced increases in peripheral adipose tissue weight, lowers blood cholesterol, suppresses platelet aggregation, reduces inflammation, increases athletic performance, protects cells, alleviates stress, and restores stress-affected sleep. These effects have been investigated primarily for octacosanol in animal models, with the full mixture studied in some human trials; heptacosanol's isolated contribution has not been delineated.

6. Body Systems and Health Areas Associated with Heptacosanol (as Part of Policosanol)

Cardiovascular system: Lipid-lowering (LDL reduction, HDL increase), platelet aggregation inhibition, blood pressure modulation, and possible anti-atherosclerotic effects. Evidence for the full policosanol mixture is inconsistent across independent studies.
Hepatic metabolism: Modulation of hepatic cholesterol biosynthesis via AMP-kinase and HMG-CoA reductase pathways. Demonstrated in cell-line and mouse studies; heptacosanol individually showed only a statistically insignificant effect in one hepatoma cell study.
Vascular system: Antiplatelet aggregation and potential endothelial function improvement; proposed benefit in intermittent claudication, though human evidence is inconclusive.
Oxidative stress / redox homeostasis: Antioxidant modulation of AOPP, TOS, TAS, SOD, and PON1 markers, studied in statin-treated cardiovascular patients using octacosanol; no heptacosanol-specific data.
Oncology (preclinical): Anticancer activity reported for the policosanol mixture in gastric cancer xenograft models; no human data and no heptacosanol-specific mechanistic evidence.
Plant physiology (native role): Heptacosanol is a structural component of plant cuticular waxes, serving as a physical defense barrier against pathogens and environmental stress.

7. Dosage Forms and Reported Dosages

7.1 Commercial Preparations

Heptacosanol is not sold or dosed as a standalone supplement. It occurs as a trace constituent within policosanol preparations. Policosanol is a natural mixture of long-chain alcohols (octacosanol, hexacosanol, nonacosanol, dotriacontanol, tetracosanol, heptacosanol, triacontanol, and tetratriacontanol) purified from sugarcane wax. Policosanol preparations contain primarily octacosanol, hexacosanol, and triacontanol; the amount of each of these alcohols can vary from product to product, and each alcohol may have different effects on the body, with effects potentially changing depending on the proportions found in any given product.

Products marketed as policosanol in the United States are often derived from beeswax or wheat germ, differing in composition from the sugarcane version and lacking robust research support.

Delivery forms for policosanol — and thus for products containing heptacosanol as a component — include tablets, capsules, and powders.

7.2 Dosages Reported in Clinical Studies

All dosages below refer to the policosanol mixture, not to heptacosanol specifically:

Policosanol is typically initiated at 5 mg/day and titrated up to 20 mg/day for hypercholesterolemia.
Adjunctive use of 40 mg/day for 30 days has been used with antiplatelet regimens after percutaneous stent implantation.
Over 1,000 subjects have been studied in 15 randomized, placebo-controlled trials using policosanol at 5 to 20 mg per day for lipid lowering.
Policosanol-induced cholesterol-lowering appears to be dose dependent in a dose range of 2–40 mg/day.
One rigorous trial conducted in Germany tested policosanol over a range of doses from 10 to 80 mg, and observed no consistent or significant impacts on lipid profiles relative to placebo.
A multicenter, randomized, double-blind trial in Cuban prehypertensive and Grade 1 hypertensive patients used a dose of 20 mg/day, with 400 patients randomized into two strata of 200 each.

8. Safety Considerations and Drug Interactions

8.1 General Tolerability

Several animal studies using doses up to 500 mg/kg in rat models did not reveal any significant drug, reproductive, or mutagenic toxicity; policosanol appears to be well tolerated and safe when given long-term in clinical trials of up to three years.

Studies in rats and mice demonstrated no adverse effects on fertility, reproduction, teratogenesis, or development at doses equivalent to 1,500 times the normal human dose of 20 mg/day.

A safety study of 27,879 people followed for 2 to 4 years showed that use of policosanol produced adverse effects in only 0.31% of participants, primarily weight loss, excessive urination, and insomnia.

8.2 Reported Adverse Effects

Quantifiable adverse effects documented in clinical surveillance include weight loss (1.8% of patients), polyuria (0.7%), and headache (0.6%); other reported adverse effects include insomnia, polyphagia, nervousness, somnolence, dizziness, erythema, excitability, hypotension, hypertension, pruritus, skin rash, nausea, epigastric pain, diarrhea, constipation, and bleeding from the nose and gums.

Increases in hepatic enzymes and creatine kinase have not been reported with policosanol.

8.3 Drug Interactions

Anticoagulants and antiplatelet agents: Because of its effects on platelet adhesiveness, policosanol can have additive effects with all anticoagulant and antiplatelet medications. However, direct evidence for heptacosanol's role in this interaction is absent; the mechanism is attributed to the policosanol mixture.

Because of policosanol's potential effects on platelet aggregation, caution is warranted if it is used concurrently with anticoagulants such as warfarin or antiplatelet agents such as aspirin, clopidogrel, or prasugrel; however, a study in 11 healthy men receiving warfarin 25 mg before and after treatment with policosanol 10 mg twice daily for 2 weeks found no effect of policosanol on the pharmacokinetics of (S)- or (R)-warfarin, and policosanol also did not alter the response to warfarin on platelet aggregation.

Beta-blockers: Experimental data indicate that potential drug–drug interactions between policosanol and drugs metabolized through the cytochrome P450 hepatic system are not expected, but pharmacodynamic interactions cannot be excluded; several clinical studies have shown that policosanol decreased arterial pressure compared with placebo, and a pharmacological interaction with beta-blockers was experimentally proven, so clinical interactions between policosanol and beta-blockers can be expected.

Calcium-channel blockers and diuretics: Cumulative data from long-term clinical trials have not indicated drug interactions or additive toxicity with calcium-channel blockers. Policosanol does not interact with calcium-channel antagonists, diuretics, and beta-blockers in terms of clinically significant adverse effects, according to observational data.

8.4 Pregnancy and Lactation

Information regarding the safety and efficacy of policosanol in pregnancy and lactation is lacking.

8.5 Product Variability

The amount of each alcohol in policosanol products can vary from product to product; each alcohol may have different effects on the body, and these effects may change depending on how much of each alcohol is found in the product; switching to a new bottle or a different brand may not produce the same effects or side effects because of this variability. This consideration applies directly to heptacosanol content, as no commercial products guarantee a specific heptacosanol concentration.

9. Current Research Status and Gaps in Evidence

Heptacosanol remains poorly studied as an independent pharmacological entity. Because policosanol is a mixture of 1-octacosanol and other molecules, its mechanism is complex and remains to be elucidated. The scientific literature on heptacosanol specifically is confined to: (1) its detection and quantification as a minor component in natural source analyses; (2) its use as a reference standard or research reagent in plant biology and lipid metabolism studies; and (3) its incidental inclusion in policosanol mixture studies.

From in vitro data, octacosanol (C28), heptacosanol (C27), and hexacosanol (C26) individually yielded smaller and statistically insignificant decreases in cholesterol synthesis relative to the full policosanol mixture, suggesting that the full mixture's activity is not simply attributable to any single component including heptacosanol.

Furthermore, 1-heptacosanol has applications in the development of novel materials including lubricants, coatings, and biodegradable polymers, where its hydrophobic properties and chemical stability are advantageous; its significance in plant biology, biochemistry, and materials science underscores its importance in advancing understanding of lipid-related processes.

The overall state of clinical evidence for policosanol as a supplement remains contested. The Cuban research group that holds the patent on sugarcane-derived policosanol has published approximately eighty double-blind studies on its product, with several thousand people enrolled in clinical trials; in virtually every one of these trials, policosanol proved more effective than placebo and as effective as statin drugs, but in science it is necessary to have independent confirmation of results before a treatment can be considered proven, and the first truly independent trials of policosanol began to appear only in 2006.

No dedicated clinical trials, systematic reviews, or meta-analyses have examined heptacosanol as a standalone dietary supplement. Any bioactivity attributed to heptacosanol in the human body rests on its minor presence within policosanol mixtures that have themselves yielded inconsistent results in independent research.